Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms × lirilumab × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Neoplasms 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Hodgkin Disease 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 40 Gemcitabine 26 Nivolumab 24 Paclitaxel 19 Cisplatin 16 Carboplatin 14 Cyclophosphamide 12 Capecitabine 12 Ipilimumab 10 Irinotecan 9 Docetaxel 9 Bevacizumab 9 Albumin-Bound Paclitaxel 9 130-nm albumin-bound paclitaxel 9 Dexamethasone 8 Rituximab 7 Pemetrexed 7 spartalizumab 6 cemiplimab 6 Temozolomide 6 Taxes 6 Sorafenib 6 Cetuximab 6 Azacitidine 6 Ascorbic Acid 6 lenvatinib 5 ibrutinib 5 fludarabine 5 Radiotherapy 5 Prednisone 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡